Since the start of the
COVID-19 pandemic, patients with diabetes were rapidly recognized as a
high-risk population for severe disease. Indeed, a high prevalence of diabetes
among patients with COVID-19 who required hospitalization has been consistently
reported, reaching 33.8% in 5,700 people hospitalized for COVID-19 in New York City area (1). In addition, diabetes was associated with more than a double risk of intensive
care unit (ICU) admission and more than a triple risk of death (2). However, precise
data regarding the type of diabetes are scarce. We report here the clinical
characteristics and early prognosis of patients with type 1 diabetes (T1D)
hospitalized for COVID-19 in the nationwide multicenter observational CORONADO (CORONAvirus-SARS-CoV-2 and Diabetes Outcomes) study (3).
The High Prevalence of Autoantibodies to Tissue Transglutaminase in First-Degree Relatives of Patients With Type 1 Diabetes Is Not Associated With Islet Autoimmunity